Compare BTBT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | FULC |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 535.5M |
| IPO Year | 2017 | 2019 |
| Metric | BTBT | FULC |
|---|---|---|
| Price | $1.57 | $7.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $6.00 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 17.8M | 921.3K |
| Earning Date | 05-14-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,560,320.00 | N/A |
| Revenue This Year | $38.96 | N/A |
| Revenue Next Year | $89.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.10 | N/A |
| 52 Week Low | $1.25 | $3.54 |
| 52 Week High | $4.55 | $15.74 |
| Indicator | BTBT | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 45.84 |
| Support Level | $1.53 | $7.40 |
| Resistance Level | $2.43 | $8.24 |
| Average True Range (ATR) | 0.10 | 0.47 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 59.09 | 39.34 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.